Abstract
G A A b st ra ct s but significantly decreased mean liver weight and the mean liver-to-body weight ratio compared to the vehicle group. Furthermore, treatment with SOLI improved glucose metabolism as evidenced by reduction of whole blood glucose levels. These changes were accompanied with a significant improvement in the histological score of NASH (NAFLD Activity Score [NAS]). There was no difference in triglycerides between the SOLI treated and vehicle treated mice. MCP-1 and MMP9 mRNA expression levels were significantly decreased in the liver. CONCLUSION: SOLI has demonstrated potential anti-NASH and anti-hyperglycemic effects in the present study. Because NAS is a clinical endpoint used to assess the treatment of NASH, these observed changes in the treatment group suggest potential for SOLI in the treatment of NASH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
